Schall, Brown & Schwartz LLP Initiates Class Action Lawsuit Against Beta Bionics, Inc. - Investors Take Note

Investor Alert: Class Action Lawsuit Against Beta Bionics, Inc.

On October 5, 2026, Schall, Brown & Schwartz LLP, a renowned firm specializing in shareholder rights litigation, announced the initiation of a federal securities class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX). This legal action targets shareholders who acquired Beta Bionics common stock between July 30, 2025, and February 24, 2026, and emphasizes important actions that affected their investments during this period.

Key Information for Investors

The lawsuit is part of a broader effort to protect the rights of investors affected by alleged misconduct. The filing in the case of Holtzman v. Beta Bionics, Inc. et al., No. 226-cv-09999 (C.D. Cal.), accuses Beta Bionics and several top executives of violating the Securities Exchange Act of 1934. Investors interested in participating have a deadline of November 3, 2026, to seek appointment as lead plaintiff in this case.

Nature of the Allegations

At the heart of the complaint are claims that Beta Bionics made false and misleading statements regarding its flagship product, the iLet Bionic Pancreas insulin pump. Throughout the specified class period, the defendants allegedly downplayed significant safety and efficacy concerns related to the device, which is specifically designed for diabetes treatment.

The complaint highlights a critical timeline during which the Company reassured investors about the device’s success despite receiving warnings from the FDA. These warnings came after an inspection where a Form 483 was issued, indicating serious concerns about the Company’s quality management systems and its failure to report incidents of serious injuries associated with the device.

Schall, Brown & Schwartz LLP asserts that these failures and reassurances from the Company led to a misrepresentation that inflated stock prices artificially. Once the truth of the FDA's findings became public, the value of Beta Bionics' shares plummeted, resulting in substantial losses for investors who had trusted the executives’ claims.

Taking Action

Shareholders of Beta Bionics who believe they have experienced losses due to these alleged violations are encouraged to get in touch with the legal team at Schall, Brown & Schwartz LLP. There are no out-of-pocket fees or costs for shareholders to join the action. Those who purchased shares during the class period can contact the litigation firm to determine their eligibility for recovery. Notably, appointment as lead plaintiff is not a requirement to participate in the class-action recovery.

About Schall, Brown & Schwartz LLP

The firm, founded by partners Brian Schall, Andrew Brown, and David Schwartz, boasts a successful track record in representing investors globally. They have collectively facilitated recoveries of over a billion dollars for violations of securities laws and corporate misconduct. Their expertise in handling securities class actions underscores their commitment to advocating for shareholders' rights.

In summary, if you are a shareholder of Beta Bionics who suffered a loss, do not hesitate to reach out to Schall, Brown & Schwartz LLP. The firm is prepared to guide you through the process and discuss your rights without any charges.

For inquiries or more information, contact the firm at their Los Angeles office, or visit their website at www.schallfirm.com.